TABLE 1.
Susceptibility profile of Enterobacter hormaechei subsp. xiangfangensis isolates carrying blaBKC-2 (Ec61), transformants, and clones carrying blaBKC-1 and blaBKC-2
| Antimicrobial agent | MIC (mg/liter) |
||||||
|---|---|---|---|---|---|---|---|
| Ec61 (wild type) | TfBKC-1 (E. coli Top10 + p60136 [blaBKC-1]) | TfBKC-2 (E. coli Top10 + pEc61C [blaBKC-2]) | Top 10 (E. coli top 10) | Cl_BKC-1 (E. coli BL21 + pET-26::blaBKC-1)a | Cl_BKC-2 (E. coli BL21 + pET-26::blaBKC-2)a | BL21 + pET26 (E. coli BL21 + pET-26) | |
| Ertapenem | 16 | 0.5 | 0.125 | ≤0.03 | 0.12 | 0.015 | 0.015 |
| Meropenem | 2 | 0.25 | 0.125 | ≤0.03 | 0.12 | 0.06 | 0.06 |
| Imipenem | 4 | 0.5 | 0.125 | ≤0.03 | 0.5 | 0.5 | 0.25 |
| Cefepime | 256 | 16 | 8 | ≤0.03 | 4 | 0.03 | 0.03 |
| Ceftazidime | >256 | 128 | 64 | 0.25 | 8 | 0.125 | 0.06 |
| Aztreonam | >256 | 256 | 64 | 0.06 | 8 | 0.03 | ≤0.015 |
| Amoxicillin | >512 | >512 | 256 | 2 | >256 | 64 | 2 |
| Ampicillin | >512 | >512 | >512 | 1 | >256 | 32 | 1 |
| Cefotaxime | 256 | 256 | 64 | 0.06 | 16 | 0.12 | ≤0.015 |
| Piperacillin-tazobactam | >256/4 | NTb | NT | NT | NT | NT | NT |
| Ceftazidime-avibactam | 2/4 | NT | NT | NT | NT | NT | NT |
| Amikacin | 256 | NT | NT | NT | NT | NT | NT |
| Gentamicin | 64 | NT | NT | NT | NT | NT | NT |
| Tobramycin | 64 | NT | NT | NT | NT | NT | NT |
| Kanamycin | >256 | NT | NT | NT | NT | NT | NT |
| Levofloxacin | 2 | NT | NT | NT | NT | NT | NT |
| Ciprofloxacin | 2 | NT | NT | NT | NT | NT | NT |
| Colistin | 1 | NT | NT | NT | NT | NT | NT |
a
BMD was performed in the presence of isopropyl-β-d-thiogalactopyranoside 0.2 mM.
b
NT, not tested.